In this study, to address the major challenges of neoantigen vaccines for tumor therapy, we demonstrated the ability of oncolytic virus to deliver neoantigen peptide-MHC complexes into tumor cells, enabling a safe and functional integration between oncolytic virus and neoantigen vaccines to suppress the growth of solid tumors in both local and regional metastatic tumor models. Here, HLA-C is linked to metastatic neoplasm.